Insights

Prescient (ASX:PTX) share price sinks despite positive update

The biotech company’s shares are taking a fall today after reaching a multi-year high yesterday.
The post Prescient (ASX:PTX) share price sinks despite positive update appeared first on The Motley Fool Australia. –

The Prescient Therapeutics Ltd (ASX: PTX) share price is freefalling today after the company provided an update on its next-generation immunotherapy platform.

At the time of writing, the Prescient share price has fallen 11%, trading at 20 cents.

Let’s take a look at the clinical stage oncology company’s news out today.

What did Prescient announce?

Investors are selling Prescient shares after the biotech announced it has completed a CAR-T manufacturing milestone. CAR-T cell therapy is a form of immunotherapy that uses laboratory altered T cells to fight cancer.

In today’s release, Prescient advised it has successfully incorporated SpyTag into a range of binders for its next-generation CAR-T programs. This includes the OmniCAR system, a breakthrough CAR T therapy platform that is believed to be a more safe and effective treatment when treating cancers.

In addition to the update, Prescient also received delivery of lentiviral vectors that will be used to produce CAR-T cells expressing SpyCatcher.

Both the binders and lentiviral vectors have been delivered to the Peter MacCallum Cancer Centre in Melbourne. Testing and in vitro (using live culture) and in vivo (using a living organism) development is expected to be undertaken.

Prescient CEO and managing director Steven Yatomi-Clarke commented:

Demonstrating that novel components can be manufactured is a crucial milestone in the development of an innovative next-generation CAR platform like OmniCAR.

… Prescient’s research team at the Peter Mac has completed all the preparatory work in parallel, and the delivery of the binders and vectors now enables the team to progress the development of our in-house next-generation cell therapies.

About the Prescient share price

Established in 1986, Prescient focuses on developing novel, personalised therapies for a range of cancers. This includes cancers such as Acute Myeloid Leukemia (AML), glioblastoma multiforme (GBM), as well as breast, ovarian and gastric cancers.

Despite today’s fall, the Prescient share price is up more than 185% in 2021, and has lifted 233% over the last 12 months. The company’s shares reached a multi-year high of 23 cents yesterday.

Prescient presides a market capitalisation of roughly $144 million, with approximately 640 million shares on issue.

The post Prescient (ASX:PTX) share price sinks despite positive update appeared first on The Motley Fool Australia.

Should you invest $1,000 in Prescient right now?

Before you consider Prescient, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Prescient wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

More reading

6 more shares that haunt fund managers

ASX copper shares up and down as copper price bounces back

Here are 3 ASX shares going ex-dividend next week

CBA (ASX:CBA) partners with Xero’s Waddle for new financing product
Wesfarmers (ASX:WES) reportedly looking to buy cancer care provider

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!